Vertex Pharmaceuticals Inc. reported an insider ownership change involving Ourania Tatsis, with the transaction dated July 21, 2026 and the Form 4 filed on July 23, 2026. The filing indicates that the reported security was Vertex common stock and that the action involved a restricted stock unit award. The explanatory note states that the RSU award vests on March 31, 2030, suggesting the transaction reflects an equity-compensation grant rather than an open-market purchase or sale. The provided filing text does not disclose the number of shares or units covered by the award, the transaction price, a transaction code, or Tatsis’s beneficial ownership following the transaction. No sale price, option exercise terms, or market transaction details are included in the excerpt. The filing was signed on Tatsis’s behalf by Christiana Stevenson, attorney-in-fact, on July 23, 2026. While limited in detail, the report is notable because Form 4 filings provide investors with timely notice of changes in insider ownership, including equity awards that align executives or insiders with shareholder interests over a future vesting period.